The significance of immune-related molecule expression profiles in an animal model of Graves' disease

References

• Mizutori Y, Chen CR, Latrofa F, McLachlan SM, Rapoport B. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease. J Clin Endocr Metab. 2009; 94:927–935.
   PubMed Web of Science ®Google Scholar
• Ludgate M. Animal models of Graves' disease. Eur J Endocrinol. 2000; 142:1–8.
   PubMed Web of Science ®Google Scholar
• Pichurin PN, Chen CR, Chazenbalk GD, Aliesky H, Pham N, Rapoport B, McLachlan SM. Targeted expression of the human thyrotropin receptor A-subunit to the mouse thyroid: Insight into overcoming the lack of response to A-subunit adenovirus immunization. J Immunol. 2006; 176:668–676.
   PubMed Web of Science ®Google Scholar
• Chazenbalk GD, Pichurin P, Chen C-R, Latrofa F, Johnstone AP, McLachlan SM, Rapoport B. Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. J Clin Invest. 2002; 110:209–217.
   PubMed Web of Science ®Google Scholar
• Chazenbalk GD, Chen C-R, McLachlan SM, Rapoport B. Does thyrotropin cleave its cognate receptor?. Endocrinology. 2004; 145:4–10.
   PubMed Web of Science ®Google Scholar
• Isaacs JD. Therapeutic T-cell manipulation in rheumatoid arthritis: Past, present and future. Rheumatology. 2008; 47:1461–1468.
   PubMed Web of Science ®Google Scholar
• McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves' hyperthyroidism from animal models. Endocr Rev. 2005; 26:800–832.
   PubMed Web of Science ®Google Scholar
• Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003; 24:802–835.
   PubMed Web of Science ®Google Scholar
• Brunner-Weinzierl MC, Hoff H, Burmester G-R. Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: Implications for arthritis and autoimmune diseases. Arthritis Res Ther. 2004; 6:45–54.
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3(+) regulatory T cell function. Science. 2008; 322:271–275.
   PubMed Web of Science ®Google Scholar
• Marks BR, Nowyhed HN, Choi JY, Poholek AC, Odegard JM, Flavell RA, Craft J. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat Immunol. 2009; 10:1125–1132.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: The Th17 lineage. Curr Opin Immunol. 2006; 18:349–356.
   PubMed Web of Science ®Google Scholar
• Nagayama Y, Kita-Furuyama M, Ando T, Nakao K, Mizuguchi H, Hayakawa T, Eguchi K, Niwa M. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol. 2002; 168:2789–2794.
   PubMed Web of Science ®Google Scholar
• Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest. 2003; 111:1897–1904.
   PubMed Web of Science ®Google Scholar
• Shah R, Banks K, Patel A, Dogra S, Terrell R, Powers PA, Fenton C, Dinauer CA, Tuttle RM, Francis GL. Intense expression of the B7-2 antigen presentation coactivator is an unfavorable prognostic indicator for differentiated thyroid carcinoma of children and adolescents. J Clin Endocr Metab. 2002; 87:4391–4397.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Zheng XF, Zhang XS, Li M, Vladau C, Ichim TE, Sun HT, Min SR, Garcia B, Min WP. Novel vaccination for allergy through gene silencing of CD40 using small interfering RNA. J Immunol. 2008; 180:8461–8469.
   PubMed Web of Science ®Google Scholar
• Chen C-R, Aliesky H, Pichurin PN, Nagayama Y, McLachlan SM, Rapoport B. Susceptibility rather than resistance to hyperthyroidism is dominant in a thyrotropin receptor adenovirus-induced animal model of Graves' disease as revealed by BALB/c-C57BL/6 hybrid mice. Endocrinology. 2004; 145:4927–4933.
   PubMed Web of Science ®Google Scholar
• Land KJ, Gudapati P, Kaplan MH, Seetharamaiah GS. Differential requirement of signal transducer and activator of transcription-4 (Stat4) and Stat6 in a thyrotropin receptor-289-adenovirus-induced model of Graves' hyperthyroidism. Endocrinology. 2006; 147:111–119.
   PubMed Web of Science ®Google Scholar
• Mizutori Y, Saitoh O, Eguchi K, Nagayama Y. Adenovirus encoding the thyrotropin receptor A-subunit improves the efficacy of dendritic cell-induced Graves' hyperthyroidism in mice. J Autoimmun. 2006; 26:32–36.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Edidin M, Almo SC, Nathenson SG. B7-1 and B7-2: Similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol Lett. 2006; 104:70–75.
   PubMed Web of Science ®Google Scholar
• Inukai Y, Momobayashi A, Sugawara N, Aso Y. Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. Eur J Endocrinol. 2007; 156:623–630.
   PubMed Web of Science ®Google Scholar
• Kallmann BA, Huther M, Tubes M, Feldkamp J, Bertrams J, Gries FA, Lampeter EF, Kolb H. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes. 1997; 46:237–243.
   PubMed Web of Science ®Google Scholar
• Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol. 2003; 170:3522–3527.
   PubMed Web of Science ®Google Scholar
• Saitoh O, Mizutori Y, Takamura N, Yamasaki H, Kita A, Kuwahara H, Nagayama Y. Adenovirus-mediated gene delivery of interleukin-10, but not transforming growth factor beta, ameliorates the induction of Graves' hyperthyroidism in BALB/c mice. Clin Exp Immunol. 2005; 141:405–411.
   PubMed Web of Science ®Google Scholar
• Nagayama Y, Saitoh O, McLachlan SM, Rapoport B, Kano H, Kumazawa Y. TSH receptor-adenovirus-induced Graves' hyperthyroidism is attenuated in both interferon-gamma and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm. Clin Exp Immunol. 2004; 138:417–422.
   PubMed Web of Science ®Google Scholar
• Ye F, Shi BY, Wu XY, Hou P, Gao L, Ma XD, Xu L, Wu LP. Experience with lentivirus-mediated CD40 gene silencing in a mouse model of Graves' disease. J Endocrinol. 2011; 208:285–291.
   PubMed Web of Science ®Google Scholar
• Faure GC, Bensoussan-Lejzerowicz D, Bene MC, Aubert V, Leclere J. Coexpression of CD40 and class II antigen HLA-DR in Graves' disease thyroid epithelial cells. Clin Immunol Immunopathol. 1997; 84:212–215.
   PubMedGoogle Scholar
• Kie JH, Cho MS, Yang WI. Expression of CD40 and apoptosis related molecules in autoimmune thyroid diseases. Yonsei Med J. 2001; 42:488–496.
   PubMed Web of Science ®Google Scholar
• Metcalfe RA, McIntosh RS, Marelli-Berg F, Lombardi G, Lechler R, Weetman AP. Detection of CD40 on human thyroid follicular cells: Analysis of expression and function. J Clin Endocrinol Metab. 1998; 83:1268–1274.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Sciaky D, Phipps RP, Jennings TA. CD40 expression in human thyroid tissue: Evidence for involvement of multiple cell types in autoimmune and neoplastic diseases. Thyroid. 1999; 9:749–755.
   PubMed Web of Science ®Google Scholar
• Tomer Y, Huber A. The etiology of autoimmune thyroid disease: A story of genes and environment. J Autoimmun. 2009; 32:231–239.
   PubMed Web of Science ®Google Scholar
• Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest. 1995; 96:987–993.
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity. 1996; 5:285–293.
   PubMed Web of Science ®Google Scholar
• Nishikawa K, Linsley PS, Collins AB, Stamenkovic I, McCluskey RT, Andres G. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur J Immunol. 1994; 24:1249–1254.
   PubMed Web of Science ®Google Scholar
• Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, Spengler U. Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol. 1999; 154:1711–1720.
   PubMed Web of Science ®Google Scholar
• Stumpf C, Lehner C, Eskafi S, Raaz D, Yilmaz A, Ropers S, Schmeisser A, Ludwig J, Daniel WG, Garlichs CD. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail. 2003; 5:629–637.
   PubMed Web of Science ®Google Scholar
• Yan J-C, Liu P-J, Du R-Z, Liang Y, Ma G-S, Zhu J, Luo D. Relationship between CD40 ligand expression and B type natriuretic peptide levels in patients with chronic heart failure. Clin Chim Acta. 2008; 392:17–20.
   PubMed Web of Science ®Google Scholar
• Santilli F, Basili S, Ferroni P, Davi G. CD40/CD40L system and vascular disease. Intern Emerg Med. 2007; 2:256–268.
   PubMed Web of Science ®Google Scholar
• Ueland T, Aukrust P, Yndestad A, Otterdal K, Froland SS, Dickstein K, Kjekshus J, Gullestad L, Damas JK. Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J. 2005; 26:1101–1107.
   PubMed Web of Science ®Google Scholar
• Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998; 391:591–594.
   PubMed Web of Science ®Google Scholar
• Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 1995; 92:4342–4346.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Iwatani Y, Hidaka Y, Watanabe M, Amino N. Long-term effects of thyroid hormone on lymphocyte subsets in spleens and thymuses of mice. Endocr J. 1995; 42:661–668.
   PubMed Web of Science ®Google Scholar
• Ziegler SF, Buckner JH. FOXP3 and the regulation of Treg/Th17 differentiation. Microbes Infect. 2009; 11:594–598.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441:235–238.
   PubMed Web of Science ®Google Scholar
• Zhou L, Lopes JE, Chong MMW, Ivanov II, Min R, Victora GD, Shen Y, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008; 453:236–240.
   PubMed Web of Science ®Google Scholar
• Dutzan N, Gamonal J, Silva A, Sanz M, Vernal R. Over-expression of forkhead box P3 and its association with receptor activator of nuclear factor-kappa B ligand, interleukin (IL) -17, IL-10 and transforming growth factor-beta during the progression of chronic periodontitis. J Clin Periodontol. 2009; 36:396–403.
   PubMed Web of Science ®Google Scholar